MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Calithera Biosciences Accounts Payables 2011-2026 | CALA
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Calithera Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.65 M | 1.99 M | 2.05 M | 1.25 M | 1.07 M | 398 K | 562 K | 693 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.65 M | 398 K | 1.46 M |
Quarterly Accounts Payables Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.01 M | 990 K | 2.12 M | 3.65 M | 2.97 M | 1.53 M | 1.64 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 2.05 M | 2.05 M | 2.05 M | 2.05 M | 1.25 M | 1.25 M | 1.25 M | 1.25 M | 1.07 M | 1.07 M | 1.07 M | 1.07 M | 398 K | 398 K | 398 K | 398 K | 562 K | 562 K | 562 K | 562 K | 693 K | 693 K | 693 K | 693 K | 150 K | 150 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.65 M | 150 K | 1.25 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
3.98 M | $ 8.64 | 8.07 % | $ 85.4 M |  USA |
 |
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
4.25 M | $ 3.11 | 5.42 % | $ 265 M | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
7.07 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | USA |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
18.5 M | - | - | $ 546 M | USA |
 |
Cabaletta Bio
CABA
|
6.64 M | $ 3.2 | 2.24 % | $ 322 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 21.36 | 4.86 % | $ 998 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.09 M | - | - | $ 169 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
2.2 M | - | - | $ 25.3 M | USA |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
21.2 M | $ 1.47 | 5.0 % | $ 378 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 2.92 | - | $ 4.81 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
29.9 M | $ 4.19 | 2.7 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 24.12 | -0.37 % | $ 3.07 B | USA |
 |
Chimerix
CMRX
|
2.85 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
2.61 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.18 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.47 | -1.34 % | $ 391 M |  Britain |
 |
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cidara Therapeutics
CDTX
|
3.61 M | - | - | $ 1.41 B | USA |
 |
CNS Pharmaceuticals
CNSP
|
1.98 M | $ 2.44 | 11.7 % | $ 1.08 M | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
2.01 M | - | - | $ 1.2 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
8.77 M | $ 4.25 | 8.35 % | $ 286 B | Britain |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |